ClinicalTrials.gg

Sleep Initiation and Maintenance Disorders clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,730 studies for Sleep Initiation and Maintenance Disorders across more than 10 countries. 731 are recruiting or about to start. 1,618 of them are mainly about Sleep Initiation and Maintenance Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 2,714 studies for Sleep Initiation and Maintenance Disorders. How that becomes 2,728 here

This page counts the studies the registry files under Sleep Initiation and Maintenance Disorders, and those it files under no condition that list Sleep Initiation and Maintenance Disordersthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 2,714Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −3List Sleep Initiation and Maintenance Disorders as a condition, but the registry did not file them under itMost often written as “Familial Fatal Insomnia” (2) and “Sleep Initiation and Maintenance Disorder; Elderly” (1). The registry filed them under other conditions only, most often Insomnia, Fatal Familial (2) and Mental Disorders (1).
  3. −17Match it another way1 name it in the title, 3 in a keyword, and 13 by a synonym or other text the search reads.
  4. 2,694Counted here and found by its search
  5. +34
    Counted here, but its search does not find themThe first 20 of 34.
  6. 2,728The count on this page

Status

Completed
1,559
Recruiting
390
Not yet recruiting
293
Status unknown
211
Terminated
88
Active, not recruiting
88

Phase

Phase 3
172
Phase 2
169
Phase 4
139
Phase 1
80
Early Phase 1
18

Where

United States
904
Turkey
391
China
198
Taiwan
123
Canada
104
Hong Kong
86

Who develops what

Add Sleep Initiation and Maintenance Disorders to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 16 programs from 8 companies, 16 with this as their studies’ main aim; 2 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Hansoh Pharmaceutical Group, Orion Corporation, Orion Pharma and Vanda Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
ZolpidemRecent, limited
Evidence
  • NCT06975514 · Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 3 · comparator · “Zolpidem” · registered May 2025
  • NCT02839200 · Idorsia Pharmaceuticals Ltd. · Phase 2 · comparator · “Zolpidem” · registered Jul 2016
  • NCT02783729 · Eisai Co., Ltd. · Phase 3 · comparator · “Zolpidem tartrate” · registered May 2016
  • NCT01181232 · Astellas Pharma Inc · Phase 4 · comparator · “Zolpidem IR” · registered Aug 2010
  • NCT00999219 · Astellas Pharma Inc · Phase 3 · background · “Zolpidem” · registered Oct 2009
Sanofi30% of its industry studiesUS: off-patent, 12 generics marketed11 study
zopicloneEarlier only
Evidence
  • NCT01100164 · eurofarma laboratorios · Phase 3 · comparator · “Zopiclone” · registered Apr 2010
  • NCT00237497 · Takeda · Phase 3 · comparator · “Zopiclone” · registered Oct 2005
Taisho Pharmaceutical Co., Ltd.33% of its industry studies00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
tasimelteonApproved: US · EU 2015☆ Track1 live phase-3 study: NCT06953869Vanda Pharmaceuticals
HS-10506☆ Track2 live phase-3 studies: NCT07677384, NCT07587385Hansoh Pharmaceutical Group Company Limited

The 2 in phase 3 with the nearest primary completion, of 16 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 1 Oct 2027 est.Low Dose Drug A, Low Dose Drug B, SOM001-A, SOM001-B, SOM001-C, SOM001-D · Somnum Pharma Inc. · Phase 2 main aimNCT07920185 A Study of Oral SOM001 as a Safe and Effective Treatment for Adults With Chronic Insomnia — primary endpoint: Number of participants with treatment-related adverse events at 3 weeks after SOM001 intervention as compared to placebo · 45 enrolled
  • Nov 2027 est.tasimelteon · Vanda Pharmaceuticals · Phase 3 main aimNCT06953869 Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia — primary endpoint: Change in sleep latency, as measured by daily sleep diary. · 420 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Sleep Initiation and Maintenance Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antipsychotics 3 open · Antiemetics 1 open · SSRIs 8 · Stimulants 7 · NK1 receptor antagonists 6

Coming up

286studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger. 59 (15%) take children under 18. 44 (11%) are for women only and 4 (1%) for men only; 109 (28%) take healthy volunteers.

Recruiting studies that take each age, of 390
AgeWomenMen
1033 (8%)33 (8%)
18258 (66%)236 (61%)
30272 (70%)248 (64%)
40283 (73%)260 (67%)
50284 (73%)254 (65%)
65277 (71%)252 (65%)
75205 (53%)191 (49%)
85167 (43%)156 (40%)

Across all 2,730 studies, recruiting or not: 50% stop at 75 or younger and 42% at 65; 10% take children; 11% are for women only and 1% for men only; 32% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Sleep Initiation and Maintenance Disorders studies take

Of 63 phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 17 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 15 mo3–20 · 39 studies4 mo1–5 · 23 studies—
Phase 217 mo12–40 · 63 studies13 mo6–16 · 27 studies—
Phase 319 mo15–28 · 42 studies18 mo9–25 · 29 studies—
Phase 428 mo17–55 · 57 studies—30 mo18–59 · 52 studies
Interventional, no phase15 mo6–34 · 1,291 studies6 mo3–23 · 78 studies15 mo6–35 · 1,213 studies
Observational18 mo4–40 · 137 studies—21 mo5–42 · 127 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered46

Show 41 more

Studies

Recruiting first, then most recently updated. Showing 50 of 2,730. Browse all 2,730 → or search them.